UB Paderborn / Katalog / Suche / in CDI

Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial

HIV medicine, 2013-01, Vol.14 (1), p.49-59

2013

Volltextzugriff (PDF)

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

Clinical infectious diseases, 2013-06, Vol.56 (11), p.1637-1645

2013

Volltextzugriff (PDF)

AN ARCHITECTURE FOR AUTOMATED FIRE DETECTION EARLY WARNING SYSTEM BASED ON GEOPROCESSING SERVICE COMPOSITION

International archives of the photogrammetry, remote sensing and spatial information sciences., 2013-09, Vol.XL-1/W3, p.351-355

2013

Volltextzugriff (PDF)

AN INTEROPERABLE ARCHITECTURE FOR AIR POLLUTION EARLY WARNING SYSTEM BASED ON SENSOR WEB

International archives of the photogrammetry, remote sensing and spatial information sciences., 2013-09, Vol.XL-1/W3, p.459-462

2013

Volltextzugriff (PDF)

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

AIDS (London), 2008-07, Vol.22 (12), p.1389-1397

2008

Volltextzugriff (PDF)

Fabrication and characterisation of chitosan/poly vinyl alcohol nanofibres via electrospinning

Materials research innovations, 2014-12, Vol.18 (sup6), p.S6-331-S6-335

2014

Volltextzugriff (PDF)

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

The Lancet infectious diseases, 2012, Vol.12 (1), p.27-35

2012

Volltextzugriff (PDF)

Preparation and characterisation of electrospun silica nanofibres

Materials research innovations, 2014-12, Vol.18 (sup6), p.S6-510-S6-514

2014

Volltextzugriff (PDF)

Abciximab and Alveolar Hemorrhage

The New England journal of medicine, 1998-12, Vol.339 (25), p.1861-1863

1998

Volltextzugriff (PDF)

Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California

AIDS patient care and STDs, 2011-09, Vol.25 (9), p.525

2011

Volltextzugriff (PDF)

Development of Kaposi sarcoma despite sustained suppression of HIV plasma viremia

Journal of acquired immune deficiency syndromes (1999), 2000-04, Vol.23 (4), p.361

2000

Volltextzugriff (PDF)

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials

Journal of antimicrobial chemotherapy, 2012-08, Vol.67 (8), p.2020-2028

2012

Volltextzugriff (PDF)

Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients

AIDS patient care and STDs, 2005-03, Vol.19 (3), p.135-140

2005

Volltextzugriff (PDF)

Heterogeneity of patients' adherence profile to antiretroviral therapy in HIV-infected patients

Journal of acquired immune deficiency syndromes (1999), 2001-11, Vol.28 (3), p.307

2001

Volltextzugriff (PDF)

Response to treatment of hepatitis C in HCV/HIV co‐infected patients is not influenced by either abacavir or tenofovir with weight‐based ribavirin

Journal of the International AIDS Society, 2010-11, Vol.13 (S4), p.P211-P211

2010

Volltextzugriff (PDF)

Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients

Journal of acquired immune deficiency syndromes (1999), 2006-01, Vol.41 (1), p.124

2006

Volltextzugriff (PDF)

Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy

AIDS (London), 2002-03, Vol.16 (5), p.797-798

2002

Volltextzugriff (PDF)

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients

Journal of acquired immune deficiency syndromes (1999), 2005-04, Vol.38 (5), p.627

2005

Volltextzugriff (PDF)

Polymyositis in HTLV‐I infected patient

Journal of internal medicine, 1996-04, Vol.239 (4), p.371-372

1996

Volltextzugriff (PDF)

A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r vs. RAL BID + ATV BID

Journal of the International AIDS Society, 2012-11, Vol.15 (S4), p.1-1

2012

Volltextzugriff (PDF)

Long-term Remission of Refractory Stiff-Man Syndrome After Treatment With Intravenous Immunoglobulin

Mayo Clinic proceedings, 1999-12, Vol.74 (12), p.1231-1232

Khanlou, Homayoun

1999

Volltextzugriff (PDF)

Relationship between Mitral valve regurgitant flow and peripartum change in systemic vascular resistance

Southern medical journal (Birmingham, Ala.), 2003-03, Vol.96 (3), p.308-309

2003

Volltextzugriff (PDF)

ARTEMIS: 192‐week efficacy and safety of once‐daily darunavir/ritonavir in treatment‐naïve HIV‐1‐infected adults

Journal of the International AIDS Society, 2010-11, Vol.13, p.3

2010

Volltextzugriff (PDF)

ARTEMIS: 192‐week efficacy and safety of once‐daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment‐naïve HIV‐1‐infected adults

Journal of the International AIDS Society, 2010-11, Vol.13 (S4), p.P3-P3

2010

Volltextzugriff (PDF)

Reduction of buffalo hump by switching to amprenavir in an HIV-infected patient

Archives of internal medicine (1960), 2000-12, Vol.160 (22), p.3499

2000

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial

SWIFT: Prospective 48-Week Study to Evaluate Efficacy and Safety of Switching to Emtricitabine/Tenofovir From Lamivudine/Abacavir in Virologically Suppressed HIV-1 Infected Patients on a Boosted Protease Inhibitor Containing Antiretroviral Regimen

AN ARCHITECTURE FOR AUTOMATED FIRE DETECTION EARLY WARNING SYSTEM BASED ON GEOPROCESSING SERVICE COMPOSITION

AN INTEROPERABLE ARCHITECTURE FOR AIR POLLUTION EARLY WARNING SYSTEM BASED ON SENSOR WEB

Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48

Fabrication and characterisation of chitosan/poly vinyl alcohol nanofibres via electrospinning

Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study

Preparation and characterisation of electrospun silica nanofibres

Abciximab and Alveolar Hemorrhage

Barriers and unmet need for supportive services for HIV patients in care in Los Angeles County, California

Development of Kaposi sarcoma despite sustained suppression of HIV plasma viremia

Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trials

Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients

Heterogeneity of patients' adherence profile to antiretroviral therapy in HIV-infected patients

Response to treatment of hepatitis C in HCV/HIV co‐infected patients is not influenced by either abacavir or tenofovir with weight‐based ribavirin

Interaction between atazanavir and fosamprenavir in the treatment of HIV-infected patients

Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy

Efficacy of tenofovir as intensification of zidovudine/lamivudine/abacavir fixed-dose combination in the treatment of HIV-positive patients

Polymyositis in HTLV‐I infected patient

A randomized pilot study of tenofovir/emtricitabine (TDF/FTC) + boosted atazanavir (ATV/r) vs. raltegravir (RAL BID) + ATV/r vs. RAL BID + ATV BID

Long-term Remission of Refractory Stiff-Man Syndrome After Treatment With Intravenous Immunoglobulin

Relationship between Mitral valve regurgitant flow and peripartum change in systemic vascular resistance

ARTEMIS: 192‐week efficacy and safety of once‐daily darunavir/ritonavir in treatment‐naïve HIV‐1‐infected adults

ARTEMIS: 192‐week efficacy and safety of once‐daily darunavir/ritonavir (DRV/r) vs lopinavir/r (LPV/r) in treatment‐naïve HIV‐1‐infected adults

Reduction of buffalo hump by switching to amprenavir in an HIV-infected patient

Suchergebnisse filtern